Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Crysvita Now Available for Self-Injection in Japan: Kyowa Kirin
December 2, 2020
- Hirosaki University to Test StemRIM’s Redasemtide for Knee Osteoarthritis
December 2, 2020
- Sosei Licenses CGRP Antagonists to Biohaven
December 2, 2020
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Takeda Closes Sale of 18 Non-Core Meds to Celltrion in Asia-Pacific
December 2, 2020
- 1st Patient Enrolled in Adoptive Trial by Amgen, Takeda, UCB: COVID R&D Alliance
December 2, 2020
- Sanofi Japan to Sharpen Focus on Priority Pipelines as It Eyes Turnaround after 2022: President
December 1, 2020
- AstraZeneca Japan Exec Vows Thorough Safety Evaluation for COVID-19 Vaccine
December 1, 2020
- Demand for Nesp Biosimilars Spiking as Hospitals Turn to Cheaper Meds in Dialysis Care, Shipment Control Triggered
December 1, 2020
- Abbott Japan Taps Managing Exec Officer Takechi as New President
December 1, 2020
- Keytruda-Chemo Combo Filed for 1st Line Esophageal Cancer in Japan
December 1, 2020
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Jardiance Filed for Chronic Heart Failure in Japan: BI/Lilly
November 30, 2020
- Sales Rep Promotions Up in All Channels in September: Intage
November 30, 2020
- Takeda Seeks Japan Nod for Zejula Tablet Form
November 27, 2020
- COVID-19 Pandemic Could Have Negative Impact of Up to 170 Billion Yen on Japan Drug Market in FY2020: IQVIA
November 27, 2020
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- Vibegron Fails in US PII Trial for IBS Pain: Urovant
November 26, 2020
- Shionogi, Nagasaki Univ., Kitasato Institute Join Forces on Antimalarial Drug Research
November 26, 2020
- Dupixent Auto-Injector Now Available: Sanofi
November 26, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…